Enfusion . Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Enfusion . Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities: | |||||||||||||
| net income | 172,000 | 1,957,000 | 2,547,000 | -761,000 | 900,000 | 2,661,000 | 998,000 | 4,694,000 | 788,000 | 2,598,000 | -4,125,000 | -12,524,000 | -293,894,000 |
| adjustments to reconcile net income to net cash from operating activities: | |||||||||||||
| non-cash lease expense | 1,829,000 | 1,752,000 | 2,037,000 | 1,765,000 | 1,651,000 | 1,975,000 | |||||||
| depreciation and amortization | 3,247,000 | 2,960,000 | 2,873,000 | 2,674,000 | 3,515,000 | 2,522,000 | 2,082,000 | 1,868,000 | 1,690,000 | 1,699,000 | 1,615,000 | 1,340,000 | 1,316,000 |
| benefit from credit losses | -71,000 | 702,000 | 213,000 | 475,000 | |||||||||
| amortization of debt-related costs | 58,000 | 59,000 | 58,000 | 59,000 | 75,000 | 4,000 | 7,000 | 6,000 | 7,000 | 6,000 | 7,000 | 6,000 | 0 |
| loss on extinguishment of debt | 0 | ||||||||||||
| stock-based compensation expense | 3,733,000 | 4,198,000 | 4,101,000 | 7,001,000 | 3,404,000 | 2,623,000 | 2,578,000 | -1,147,000 | 4,205,000 | 438,000 | 7,668,000 | 12,682,000 | |
| change in operating assets and liabilities: | |||||||||||||
| accounts receivable | -123,000 | 1,854,000 | -3,156,000 | -2,722,000 | -3,141,000 | -390,000 | -1,026,000 | 878,000 | 2,999,000 | -1,023,000 | -5,697,000 | -5,310,000 | -396,000 |
| prepaid expenses and other assets | -1,828,000 | 509,000 | 723,000 | -1,153,000 | -972,000 | ||||||||
| accounts payable | -306,000 | 382,000 | -2,572,000 | 1,311,000 | 707,000 | 475,000 | -422,000 | -395,000 | 540,000 | 587,000 | -631,000 | -1,339,000 | 219,000 |
| accrued compensation | 2,393,000 | 2,926,000 | 1,901,000 | -3,545,000 | 1,462,000 | 1,790,000 | |||||||
| accrued expenses and other liabilities | 1,603,000 | 1,244,000 | 283,000 | -455,000 | 1,197,000 | 787,000 | 4,637,000 | -4,262,000 | 910,000 | 1,805,000 | 2,388,000 | 938,000 | -4,275,000 |
| lease liabilities | -1,778,000 | -1,491,000 | -1,402,000 | -1,593,000 | -1,269,000 | -1,646,000 | |||||||
| other non-current liabilities | |||||||||||||
| net cash from operating activities | 9,673,000 | 16,162,000 | 7,314,000 | 1,533,000 | 6,586,000 | 12,106,000 | 6,018,000 | 924,000 | 7,521,000 | -5,812,000 | |||
| capex | -891,000 | -1,104,000 | -1,005,000 | -635,000 | 2,923,000 | -2,607,000 | -2,219,000 | -2,550,000 | -1,746,000 | -1,641,000 | |||
| free cash flows | 8,782,000 | 15,058,000 | 6,309,000 | 898,000 | 9,509,000 | 9,499,000 | 3,799,000 | -1,626,000 | 5,775,000 | -7,453,000 | |||
| cash flows from investing activities: | |||||||||||||
| purchases of property and equipment | -891,000 | -1,104,000 | -1,005,000 | -635,000 | 2,923,000 | -2,607,000 | -2,219,000 | -2,550,000 | -1,746,000 | -922,000 | -2,092,000 | -3,171,000 | -1,641,000 |
| capitalization of software development costs | -1,772,000 | -1,671,000 | -1,701,000 | -2,113,000 | |||||||||
| purchase of convertible promissory note | 0 | 0 | |||||||||||
| net cash from investing activities | -2,663,000 | -2,775,000 | -5,706,000 | -2,748,000 | -2,295,000 | -2,607,000 | -2,219,000 | -2,550,000 | -1,746,000 | -922,000 | -2,092,000 | -3,171,000 | |
| cash flows from financing activities: | |||||||||||||
| distributions to non-controlling interests | 0 | 0 | -35,000 | -101,000 | |||||||||
| settlement of tax receivable acquired in reorganization transactions | 0 | ||||||||||||
| issuance of class a common stock, net of issuance costs | 0 | 7,630,000 | |||||||||||
| payment of withholding taxes on stock-based compensation | 0 | -14,000 | 19,000 | -1,272,000 | -579,000 | -11,788,000 | -40,501,000 | -7,579,000 | -7,042,000 | -20,000 | -92,000 | -805,000 | |
| payment of debt issuance and debt facility costs | |||||||||||||
| other financing activities | 0 | ||||||||||||
| net cash from financing activities | 0 | -14,000 | -16,000 | -1,373,000 | -579,000 | -5,309,000 | -30,842,000 | -6,353,000 | -7,042,000 | -20,000 | -92,000 | -805,000 | 63,382,000 |
| effect of exchange rate changes on cash and cash equivalents | -829,000 | 479,000 | -39,000 | -122,000 | 240,000 | -309,000 | |||||||
| net increase in cash and cash equivalents | 6,181,000 | ||||||||||||
| cash and cash equivalents, beginning of period | 0 | 0 | 0 | 35,604,000 | 0 | 0 | 0 | 62,545,000 | 0 | ||||
| cash and cash equivalents, end of period | 6,181,000 | 13,852,000 | 1,553,000 | 32,894,000 | 3,952,000 | 3,881,000 | -26,827,000 | 54,598,000 | -998,000 | ||||
| supplemental disclosure of cash flow information: | |||||||||||||
| income taxes paid in cash | 1,205,000 | 307,000 | 166,000 | 372,000 | 1,245,000 | 260,000 | 133,000 | 205,000 | 529,000 | 720,000 | 68,000 | 265,000 | |
| supplemental disclosure of non-cash activities: | |||||||||||||
| right-of-use assets obtained in exchange for lease liabilities | 3,752,000 | 1,150,000 | 3,661,000 | 1,318,000 | 0 | 5,355,000 | |||||||
| capitalized stock-based compensation expense | 186,000 | 197,000 | 190,000 | 389,000 | 275,000 | 220,000 | 162,000 | 109,000 | 100,000 | ||||
| accrued property, equipment, and software | 186,000 | 257,000 | 189,000 | 168,000 | |||||||||
| benefit from credit (benefit) losses | |||||||||||||
| other operating activities | |||||||||||||
| prepaid expenses | 907,000 | 947,000 | -414,000 | ||||||||||
| other assets | -233,000 | -713,000 | -1,646,000 | ||||||||||
| net decrease in cash and cash equivalents | 1,553,000 | -2,710,000 | 3,881,000 | ||||||||||
| benefit for credit losses | -141,000 | ||||||||||||
| payment of debt issuance costs | |||||||||||||
| repayment of term loan | -98,750,000 | ||||||||||||
| payment of member distributions | 0 | ||||||||||||
| purchases of common units from pre-ipo common unit holders | |||||||||||||
| interest paid in cash | |||||||||||||
| effect of the reorganization transactions | |||||||||||||
| ipo costs included in accrued expenses and other liabilities | |||||||||||||
| other | -33,000 | -275,000 | |||||||||||
| supplemental disclosure of non-cash investing activities: | |||||||||||||
| accrued property and equipment | |||||||||||||
| settlement of tax receivable acquired in reorganization transaction | 0 | 1,501,000 | |||||||||||
| non-cash operating lease expense | -40,000 | ||||||||||||
| effect of exchange rate changes on cash | 32,000 | 269,000 | 84,000 | -353,000 | -86,000 | 4,000 | |||||||
| net decrease in cash | -7,947,000 | 6,984,000 | 353,000 | -8,159,000 | |||||||||
| cash paid for amounts included in the measurement of lease liabilities | 1,478,000 | ||||||||||||
| | |||||||||||||
| benefit from bad debts | 138,000 | 802,000 | 336,000 | 123,000 | 1,172,000 | ||||||||
| net foreign currency losses | |||||||||||||
| prepaid expenses and other current assets | -4,013,000 | 930,000 | 1,329,000 | -13,000 | |||||||||
| proceeds from term loan | |||||||||||||
| issuance of class d units, net of issuance costs | |||||||||||||
| proceeds from draw on revolving debt facility | |||||||||||||
| redemption of class a units | |||||||||||||
| distribution of loan proceeds to members | |||||||||||||
| repayment of draw on revolving debt facility | |||||||||||||
| payment of equity issuance costs on non-cash issuance of class d units | |||||||||||||
| issuance of class a common stock in the ipo, net of issuance costs | |||||||||||||
| supplemental disclosure of non-cash financing activities: | |||||||||||||
| issuance of class d units in a non-cash exchange for class c-1 and c-2 units | |||||||||||||
| accrued property, plant and equipment | -281,000 | ||||||||||||
| net cash (used) provided by operating activities | 2,890,000 | -4,097,000 | |||||||||||
| cash, beginning of period | 0 | 64,365,000 | 0 | ||||||||||
| cash, end of period | 353,000 | 56,206,000 | 55,933,000 | ||||||||||
| ● | |||||||||||||
| net cash (used in) investing activities | |||||||||||||
| issuance of class c-2 units, net of issuance costs | |||||||||||||
| purchase of common units from pre-ipo common unit holders | |||||||||||||
| net increase in cash | 55,933,000 | ||||||||||||
| interest paid | |||||||||||||
| level 1 |
We provide you with 20 years of cash flow statements for Enfusion . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Enfusion . stock. Explore the full financial landscape of Enfusion . stock with our expertly curated income statements.
The information provided in this report about Enfusion . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.